← Trials/Trial dossier/NCT05037045
Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM
Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University
Asset
GLP-1 / incretin class catch-all
Subcutaneous
Listed sites
1
Recruiting sites
—
Enrollment
338
actual
Study population
Type 2 diabetes
Key I/E criteria
•BMI 20-35•HbA1c 7-12%
Primary endpoints
•HbA1c, change•Fasting glucose, change•Postprandial glucose
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
1. a diagnosis of T2DM；
2. a body mass index (BMI) of 20-35 kg/m2；
3. an HbA1c of 7.0%-12%, an age of 25-70 years；
4. required data available at baseline, 3 months, and 6 months after GLP-1 RA therapy.
Exclusion criteria
1. Patients with serious diseases such as acute myocardial infarction, cerebral vascular accident, trauma, kidney or liver diseases, severe gastrointestinal dysfunction, and history of pancreatitis；
2. patients receiving GLP-1 analogues, weight loss drugs, glucocorticoids, drugs affecting gastrointestinal peristalsis in the past 3 months；
3. those with missing data at the time points of baseline, 3 months, and 6 months after GLP-1 RA therapy.
Endpoints (15)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Glycemic / diabetes
9 endpointsChange from baseline HbA1c at 1 month
Time frame:1 month after GLP-1 RA treatment
HbA1c, change
change from baseline, improvement
LOINC 4548-4
Change from baseline FPG at 1 month
Time frame:1 month after GLP-1 RA treatment
Fasting glucose, change
change from baseline, improvement
LOINC 1558-6
Change from baseline PPG at 1 month
Time frame:1 month after GLP-1 RA treatment
Postprandial glucose
change from baseline, improvement
Change from baseline HbA1c at 3 month
Time frame:3 month after GLP-1 RA treatment
HbA1c, change
change from baseline, improvement
LOINC 4548-4
Change from baseline FPG at 3 month
Time frame:3 month after GLP-1 RA treatment
Fasting glucose, change
change from baseline, improvement
LOINC 1558-6
Change from baseline PPG at 3 month
Time frame:3 month after GLP-1 RA treatment
Postprandial glucose
change from baseline, improvement
Change from baseline HbA1c at 6 month
Time frame:6 month after GLP-1 RA treatment
HbA1c, change
change from baseline, improvement
LOINC 4548-4
Change from baseline FPG at 6 month
Time frame:6 month after GLP-1 RA treatment
Fasting glucose, change
change from baseline, improvement
LOINC 1558-6
Change from baseline PPG at 6 month
Time frame:6 month after GLP-1 RA treatment
Postprandial glucose
change from baseline, improvement
Cardiometabolic biomarkers
3 endpointsChange from baseline serum lipids at 1 month
Time frame:1 month after GLP-1 RA treatment
change from baseline, improvement
Change from baseline serum lipids at 3 month
Time frame:3 month after GLP-1 RA treatment
change from baseline, improvement
Change from baseline serum lipids at 6 month
Time frame:6 month after GLP-1 RA treatment
change from baseline, improvement
Safety / tolerability / PK
3 endpointsincidence and severity of possible adverse reaction within 1 month after GLP-1 RA treatment
Time frame:1 month after GLP-1 RA treatment
Treatment-emergent AEs (any)
descriptive, event
incidence and severity of possible adverse reaction within 3 month after GLP-1 RA treatment
Time frame:3 month after GLP-1 RA treatment
descriptive, event
componentsTreatment-emergent AEs (any), Nausea, Vomiting, Diarrhea, Documented hypoglycemia
incidence and severity of possible adverse reaction within 6 month after GLP-1 RA treatment
Time frame:6 month after GLP-1 RA treatment
descriptive, event
componentsNausea, Vomiting, Diarrhea, Documented hypoglycemia
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.